Creating a shared Risk Evaluation and Mitigation Strategy (REMS) program for the antipsychotic clozapine has proven to be more difficult than FDA anticipated. Last month, the agency announced that technical issues with the program had resolved, but on Nov. 13 reported that health care professionals were continuing to have problems with it.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?